Patents by Inventor Lieve Adriaens

Lieve Adriaens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
    Patent number: 11919965
    Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides methods for treating multiple myeloma using bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: March 5, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Israel Lowy, David Sternberg, Manish Sharma, Lieve Adriaens
  • Methods of Treating Multiple Myeloma with Bispecific Anti-BCMA x Anti-CD3 Antibodies
    Publication number: 20210206865
    Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides methods for treating multiple myeloma using bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA.
    Type: Application
    Filed: December 4, 2020
    Publication date: July 8, 2021
    Inventors: Israel Lowy, David Sternberg, Manish Sharma, Lieve Adriaens